Q2 2025 · 13F-HR
PERCEPTIVE ADVISORS LLCholdings as filed
Filed 2025-08-14 · accession 0001012975-25-000446
$2.70B
Reported value
85
Positions
2025-06-30
Period end
The Brief · PERCEPTIVE ADVISORS LLC · Q2 2025
AI · grounded in 13F
PERCEPTIVE ADVISORS LLC established a new position in VRNA valued at $520.9M. The fund also initiated new stakes in ASNDUSD for $166.4M and ACLXGBX for $163.2M. Additional new positions include RYTM at $152.8M and NUVL at $104.9M. Total assets under management stand at $2.7B across 84 positions.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 925050106 | VRNA | VERONA PHARMA PLC | $520.9M | 19.3% | 5,507,591 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $166.4M | 6.17% | 963,886 | Common | SOLE |
| 03940C100 | ACLXGBX | ARCELLX INC | $163.2M | 6.05% | 2,478,000 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $152.8M | 5.67% | 2,418,299 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $104.9M | 3.89% | 1,375,180 | Common | SOLE |
| 228903100 | AORT | ARTIVION INC | $86.9M | 3.22% | 2,793,703 | Common | SOLE |
| G59665102 | MGTX | MEIRAGTX HLDGS PLC | $82.2M | 3.05% | 12,626,103 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $65.4M | 2.43% | 650,252 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $60.8M | 2.26% | 4,639,949 | Common | SOLE |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $59.4M | 2.20% | 1,074,448 | Common | SOLE |
| 83422E204 | SLDB | SOLID BIOSCIENCES INC | $58.0M | 2.15% | 11,906,646 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $51.3M | 1.90% | 1,182,148 | Common | SOLE |
| 03237H101 | AMLX | AMYLYX PHARMACEUTICALS INC | $50.7M | 1.88% | 7,902,365 | Common | SOLE |
| N44445109 | IMTX | IMMATICS N.V | $50.5M | 1.87% | 9,383,456 | Common | SOLE |
| 00973Y108 | AKRO | AKERO THERAPEUTICS INC | $48.9M | 1.81% | 915,887 | Common | SOLE |
| 68170A108 | OMDA | OMADA HEALTH INC | $44.4M | 1.65% | 2,426,330 | Common | SOLE |
| 03152W109 | AM6 | AMICUS THERAPEUTICS INC | $42.5M | 1.57% | 7,412,830 | Common | SOLE |
| G76279101 | ROIV | ROIVANT SCIENCES LTD | $37.5M | 1.39% | 3,331,465 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $37.3M | 1.38% | 708,176 | Common | SOLE |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $36.1M | 1.34% | 430,439 | Common | SOLE |
| 04635X102 | CATBUSD | ASTRIA THERAPEUTICS INC | $34.8M | 1.29% | 6,485,420 | Common | SOLE |
| 45258J102 | IMVT | IMMUNOVANT INC | $34.2M | 1.27% | 2,137,890 | Common | SOLE |
| 64125C109 | NBIX | NEUROCRINE BIOSCIENCES INC | $32.1M | 1.19% | 255,050 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $31.7M | 1.17% | 752,921 | Common | SOLE |
| 101137107 | BSX | BOSTON SCIENTIFIC CORP | $30.1M | 1.11% | 280,000 | Common | SOLE |
| 142152107 | CAI | CARIS LIFE SCIENCES INC | $29.3M | 1.09% | 1,098,163 | Common | SOLE |
| 78464A870 | XBI | SPDR SERIES TRUST | $24.9M | 0.92% | 300,000 | PUT | SOLE |
| 46120E602 | ISRG | INTUITIVE SURGICAL INC | $24.5M | 0.91% | 45,119 | Common | SOLE |
| 000899104 | ADMA | ADMA BIOLOGICS INC | $23.7M | 0.88% | 1,303,468 | Common | SOLE |
| 08659B102 | BBNX | BETA BIONICS INC | $23.2M | 0.86% | 1,593,608 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $22.9M | 0.85% | 1,529,445 | Common | SOLE |
| 30052C107 | EOLS | EVOLUS INC | $22.8M | 0.85% | 2,474,843 | Common | SOLE |
| 15102K100 | CELC | CELCUITY INC | $21.8M | 0.81% | 1,633,208 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $21.4M | 0.79% | 2,247,390 | Common | SOLE |
| 829401108 | SION | SIONNA THERAPEUTICS INC | $21.1M | 0.78% | 1,216,045 | Common | SOLE |
| 05464T104 | AXSM | AXSOME THERAPEUTICS INC | $20.7M | 0.77% | 198,534 | Common | SOLE |
| 759916109 | RGEN | REPLIGEN CORP | $20.6M | 0.77% | 166,000 | Common | SOLE |
| 45784P101 | PODD | INSULET CORP | $19.0M | 0.70% | 60,387 | Common | SOLE |
| 690145206 | OM | OUTSET MED INC | $16.0M | 0.59% | 833,333 | Common | SOLE |
| 98985Y108 | ZYME | ZYMEWORKS INC | $16.0M | 0.59% | 1,275,274 | Common | SOLE |
| 23284F105 | CTMX | CYTOMX THERAPEUTICS INC | $15.9M | 0.59% | 6,993,646 | Common | SOLE |
| 01438T106 | ALDX | ALDEYRA THERAPEUTICS INC | $15.5M | 0.58% | 4,051,631 | Common | SOLE |
| 159864107 | CRL | CHARLES RIV LABS INTL INC | $15.2M | 0.56% | 100,000 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $15.1M | 0.56% | 1,146,935 | Common | SOLE |
| 45720N103 | INBX | INHIBRX BIOSCIENCES INC | $14.0M | 0.52% | 977,892 | Common | SOLE |
| 00534B100 | ADGM | ADAGIO MED HLDGS INC | $12.8M | 0.48% | 9,876,576 | Common | SOLE |
| 67080M103 | NRIX | NURIX THERAPEUTICS INC | $12.5M | 0.46% | 1,096,985 | Common | SOLE |
| 89422G107 | TVTX | TRAVERE THERAPEUTICS INC | $12.3M | 0.46% | 834,252 | Common | SOLE |
| 68572M106 | OBIO | ORCHESTRA BIOMED HLDGS INC | $12.3M | 0.46% | 4,592,556 | Common | SOLE |
| 10919W405 | DRUG | BRIGHT MINDS BIOSCIENCES INC | $11.0M | 0.41% | 420,690 | Common | SOLE |
| 45719W205 | IKT | INHIBIKASE THERAPEUTICS INC | $10.6M | 0.39% | 5,432,293 | Common | SOLE |
| 92686J106 | VKTX | VIKING THERAPEUTICS INC | $10.1M | 0.37% | 380,700 | Common | SOLE |
| 90400D108 | RARE | ULTRAGENYX PHARMACEUTICAL IN | $9.8M | 0.36% | 270,000 | Common | SOLE |
| 501575104 | KYMR | KYMERA THERAPEUTICS INC | $9.2M | 0.34% | 210,106 | Common | SOLE |
| 63909J108 | NAUT | NAUTILUS BIOTECHNOLOGY INC | $9.1M | 0.34% | 12,594,211 | Common | SOLE |
| 70975L107 | PEN | PENUMBRA INC | $8.4M | 0.31% | 32,797 | Common | SOLE |
| G2545C104 | CBIO | CRESCENT BIOPHARMA INC. | $7.3M | 0.27% | 453,686 | Common | SOLE |
| 03843E104 | AQST | AQUESTIVE THERAPEUTICS INC | $7.3M | 0.27% | 2,190,420 | Common | SOLE |
| 47103J105 | JANX | JANUX THERAPEUTICS INC | $6.8M | 0.25% | 292,686 | Common | SOLE |
| 03675P102 | AVR | ANTERIS TECHNOLOGIES GLOBAL | $6.5M | 0.24% | 1,705,130 | Common | SOLE |
| 14070B309 | CAPR | CAPRICOR THERAPEUTICS INC | $6.5M | 0.24% | 650,000 | PUT | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $6.3M | 0.23% | 200,791 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $6.3M | 0.23% | 447,507 | Common | SOLE |
| 221015100 | CRVS | CORVUS PHARMACEUTICALS INC | $5.8M | 0.21% | 1,438,595 | Common | SOLE |
| 81734D104 | SEPN | SEPTERNA INC | $5.7M | 0.21% | 541,450 | Common | SOLE |
| 379577208 | GMED | GLOBUS MED INC | $5.2M | 0.19% | 88,500 | Common | SOLE |
| 29415J106 | NVNO | ENVVENO MEDICAL CORPORATION | $5.1M | 0.19% | 1,284,966 | Common | SOLE |
| G4444H101 | BBOT | HELIX ACQUISITION CORP II | $4.2M | 0.16% | 398,000 | Common | SOLE |
| 67577R102 | IRD | OPUS GENETICS INC | $4.1M | 0.15% | 4,325,000 | Common | SOLE |
| 21217B100 | CTNM | CONTINEUM THERAPEUTICS INC | $2.8M | 0.10% | 699,486 | Common | SOLE |
| 55234L204 | LYRA | LYRA THERAPEUTICS INC | $2.3M | 0.08% | 255,150 | Common | SOLE |
| 810648105 | SCPH | SCPHARMACEUTICALS INC | $1.9M | 0.07% | 500,000 | Common | SOLE |
| 04746L104 | — | ATHIRA PHARMA INC | $1.6M | 0.06% | 5,402,964 | Common | SOLE |
| 75382E208 | RAPT | RAPT THERAPEUTICS INC | $1.5M | 0.05% | 183,890 | Common | SOLE |
| 896438504 | TRIB | TRINITY BIOTECH PLC | $1.2M | 0.04% | 1,790,000 | Common | SOLE |
| 14070B309 | CAPR | CAPRICOR THERAPEUTICS INC | $993,000 | 0.04% | 100,000 | CALL | SOLE |
| 34962G208 | FBRX | FORTE BIOSCIENCES INC | $881,723 | 0.03% | 68,192 | Common | SOLE |
| 05338F306 | AVTX | AVALO THERAPEUTICS INC | $696,938 | 0.03% | 139,667 | Common | SOLE |
| 09075X108 | BDSX | BIODESIX INC | $613,034 | 0.02% | 2,173,880 | Common | SOLE |
| 52886X107 | LXEO | LEXEO THERAPEUTICS INC | $562,137 | 0.02% | 139,835 | Common | SOLE |
| 03837C106 | APYX | APYX MEDICAL CORPORATION | $337,500 | 0.01% | 150,000 | Common | SOLE |
| 483119202 | KALAEUR | KALA BIO INC | $262,881 | 0.01% | 55,227 | Common | SOLE |
| 293602504 | ENSC | ENSYSCE BIOSCIENCES INC | $193,265 | 0.01% | 86,666 | Common | SOLE |
| 76155X118 | RVMDW | REVOLUTION MEDICINES INC | $65,675 | 0.00% | 250,000 | Common | SOLE |
| 86889P117 | SRZNW | SURROZEN INC | $3,017 | 0.00% | 166,666 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.